Technology

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

5 years ago

Anonymous $Dftgs0JzgE

https://www.businesswire.com/news/home/20190331005030/en/

ATLANTA--(BUSINESS WIRE)--Mar 31, 2019--F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, will present four abstracts at the American Association of Cancer Research (AACR) 2019 Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel technologies to treat solid tumor malignancies.
F1 Oncology is developing these novel CAB-CAR-T therapies to target solid tumors while minimizing the potential of on-target, off-tumor activity. The four abstracts provide insight into the use of the company’s proprietary CAB-CAR-T technology to increase the potential safety of CAR-T therapeutics by turning the negative effects of the tumor microenvironment (TME) into activating signals. They will highlight proof of concept studies of same-day, point of care CAR-T and use bioinformatics data driven methods to discover protein domain combinations capable of selectively expanding CAR-T cells.

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

Mar 31, 2019, 6:15pm UTC

$Dftgs0JzgE

https://www.businesswire.com/news/home/20190331005030/en/ > ATLANTA--(BUSINESS WIRE)--Mar 31, 2019--F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, will present four abstracts at the American Association of Cancer Research (AACR) 2019 Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel technologies to treat solid tumor malignancies. > F1 Oncology is developing these novel CAB-CAR-T therapies to target solid tumors while minimizing the potential of on-target, off-tumor activity. The four abstracts provide insight into the use of the company’s proprietary CAB-CAR-T technology to increase the potential safety of CAR-T therapeutics by turning the negative effects of the tumor microenvironment (TME) into activating signals. They will highlight proof of concept studies of same-day, point of care CAR-T and use bioinformatics data driven methods to discover protein domain combinations capable of selectively expanding CAR-T cells.